Factors associated with improvement in deceased donor renal allograft function in the 1990s

Journal of the American Society of Nephrology

Volumn 16, Issue 5, 2005, Pages 1512-1521

  Keith, Douglas S ^a   DeMattos, Angelo ^b   Golconda, Muralikrishna ^c   Prather, Jonathan ^c   Cantarovich, Marcelo ^a   Paraskevas, Steven ^a   Tchervenkov, Jean ^a   Norman, Douglas J ^c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b University of Alabama at Birmingham   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CADAVER DONOR; CADAVER KIDNEY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; ACUTE DISEASE; ADOLESCENT; AGED; ALLOTRANSPLANTATION; DONOR; FEMALE; KIDNEY; MALE; MIDDLE AGED; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 23944471751     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004090813     Document Type: Article

References (16)

1. Hariharan S. McBride M, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62: 311-318, 2002
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612, 2000
3. Meier-Kriesche H, Schold JD, Kaplan B: Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295, 2004
4. Manjunath G, Sarnak MJ, Levey AS: Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 10: 785-792, 2001
5. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J: Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 9: 2129-2134, 1998
6. Gloor JM, Cohen AJ, Lager DJ, Grande JP, Fidler ME, Velosa JA, Larson TS, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Sterioff S, Kremers WK, Stegall MD: Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 73: 1965-1968, 2002
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Alien RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
8. Lipman M, Lavery P, Shi Y, Shen Y, Aalamian Z, Loertscher R: Incidence of subclinical rejection in protocol biopsies procured from renal transplant recipients on tacrolimus-based immunosuppression regimen [Abstract]. Am J Transplant 4[Suppl 8]: 551, 2004
9. Kaplan B, Schold JD, Meier-Kriesche HU: Long-term graft survival with Neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 14: 2980-2984, 2003
10. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920-929, 2002
11. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT; Rapamune Maintenance Regimen Study Group: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76: 364-370, 2003
12. Baboolal K: A phase cross D sign Éprospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75: 1404-1408, 2003
13. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002
14. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG; Sirolimus European Renal Transplant Study Group: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2: 436-442, 2002
15. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001
16. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000